Brain MRI, tau and amyloid PET, and cerebrospinal fluid (CSF) biomarkers are increasingly used in the clinical diagnosis of AD [5–7] to detect the presence of neurodegeneration, abnormal amyloid peptides, or pathologic tau proteins in the brain. This evidence concerns the gene MAPT and Alzheimer disease.